Biography & Net Worth: Moderna COVID-19 vaccine effective against viral variants: research

credit: AIXabay / CC0 Public Domain

A study by Kaiser Permanente published on December 15, 2021 british medical journal Two doses of the Modelna COVID-19 vaccine have been shown to be highly effective against all SARS-CoV-2 mutants. However, there has been a slight decline in the effectiveness of the vaccine against the delta variant with increasing post-vaccination time.

“We conducted previous studies and the high efficacy of the double dose modern COVID-19 vaccine, but as the delta version became dominant in early 2021, a question arose against the mutants. Katia Brooksvoort, PhD, deputy research fellow at the Southern California Bureau of Research and Evaluation, said study lead author Kaiser Permanente.

“This study confirmed efficacy against all mutants during the study period, but the efficacy against delta infection is 6 months, from 94% efficacy in the first 2 months after vaccination. This was subsequently reduced to 80%. delta For the variant, it remained high at 98% efficacy.”

At Kaiser Permanente in Southern California, the SARS-CoV-2 molecular diagnostics test is free to members who request it, regardless of whether they have symptoms of COVID-19. The test is also done before hospitalization and many medical procedures. Starting in March 2021, Kaiser Permanente of Southern California began sending positive SARS-CoV-2 samples from both symptomatic and asymptomatic people to contracted laboratories for whole-genome sequencing.

The Moderna-funded study involved 8,153 people who were positive for SARS-CoV-2 and samples were collected from March 1, 2021 to July 27, 2021. 19 vaccines, 7.3% were given the Modern COVID-19 vaccine twice.

Of these, variants in 5,186 samples were identified. 39.4% were delta, 27.7% alpha, 11.4% epsilon, 6.9% gamma, 2.2% iota, 1.4% mu, and 11.1% other variants. At the time of this study, the Omicron variant had not yet been detected in the Southern California region.

The researchers compared those who tested positive to those who tested negative. Researchers have found the following:

  • Modern COVID-19 vaccine efficacy against infection by two dose variants:
    • Delta: 86.7%
    • mu: 90.4%
    • Alpha: 98.4%
    • Other Identified Variants: 96-98%
  • People receiving the two-dose Moderna COVID-19 vaccine were strongly protected from Delta-related COVID-19 hospitalizations. Mutant:
    • Vaccine efficacy was as high as 97.5% for Delta hospitalizations
    • Vaccine efficacy was not estimated for non-delta mutation hospitalizations because there were no hospitalizations in which non-delta mutations were identified among those who were vaccinated.
  • There were no deaths from hospitalization among those receiving the two-dose Moderna COVID-19 vaccine.
  • The efficacy of the two-dose Moderna COVID-19 vaccine against delta infection was 87.9% for people aged 18-64 years and 75.2% for those aged 65 years and older.

“This study provides solid evidence of the efficacy of double-dose modern COVID-19 vaccine in the prevention of COVID-19 infection and hospitalization due to deltas-containing mutations, but also of booster shots.” Hung Fu, lead author of the study, said. Dr. Zane, a researcher at Kaiser Permanente Southern California Research and Evaluation Bureau. “The findings that there was a slight decrease in vaccine efficacy of Moderna COVID-19 as time passed by Delta Infectious Diseases support the current booster dose recommendations. ,

Moderna COVID-19 Vaccine Effective 5 Months After Second Dose

for more information:
Efficacy of mRNA-1273 against delta, mu, and other novel variants of SARS-CoV-2: trial-negative case-control study, british medical journal (2021). DOI: 10.1136/bmj-2021-068848,

provided by
Kaiser Permanente

Citation:effective-modern COVID-19 vaccine against viral variants: study (2021, December 15, 2021) .html

This document is subject to copyright. No part may be reproduced without written permission, except in reasonable transactions for personal investigation or research purposes. The content is provided for informational purposes only.